Shanghai Pharmaceuticals (601607) Q1 2026 earnings summary

Executive summary

• Achieved stable growth with revenue of RMB 75.26 billion, up 6.36% year-over-year for Q1 2026.

• Net profit attributable to shareholders reached RMB 1.42 billion, up 6.35% year-over-year.

• Industrial segment sales grew 15.64% and commercial segment sales rose 5.52% year-over-year.

• R&D investment was RMB 577 million, 8.47% of industrial sales.

Financial highlights

• Operating income: RMB 75.26 billion, up 6.36% year-over-year.

• Net profit attributable to shareholders: RMB 1.42 billion, up 6.35% year-over-year.

• Adjusted net profit (excluding non-recurring items): RMB 1.24 billion, down 2.02% year-over-year.

• Basic and diluted EPS: RMB 0.3823, up 6.35% year-over-year.

• Operating cash flow: -RMB 1.01 billion, improved from -RMB 2.20 billion year-over-year.

Outlook and guidance

• Continued focus on new drug R&D and commercialization.

• Ongoing digital transformation and integration of new retail strategies.